Bicara reports FY2025 net loss $138M; cash $414.8M; raises $161.8M in public offering

Bicara Therapeutics Inc.

Net loss Q4 2025 $37.4M, full year $138.0M vs $21.0M and $68.0M in 2024.
R&D expenses $33.0M Q4, $125.1M full year; G&A $8.1M Q4, $30.5M full year.
Cash & securities $414.8M at Dec 31, 2025; added $161.8M net from Q1 2026 offering; expected runway into H1 2029.
Selected 1500mg weekly ficerafusp alfa for Phase 3; initiated FORTIFI-HN01 trial; interim analysis expected mid-2027.
Developing a loading and every-three-week maintenance dose for potential U.S. approval.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bicara Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss totaled $37.4 million and $138.0 million for the fourth quarter and full year ended December 31, 2025, respecti.

Period: the fourth quarter and full year ended December 31, 2025
Net income: Net loss totaled $37.4 million and $138.0 million for the fourth quarter and full year ended December 31, 2025, respecti
Result: reported results

Exact text from the filing

On March 30, 2026, Bicara Therapeutics Inc. (the "Company") issued a press release announcing its financial results and business highlights for the fiscal year and quarter ended December 31, 2025.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Bicara Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-021868

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.